CycloGen AI

News & Announcements

Updates on our AI drug discovery platform, proprietary therapeutic programs, and company developments.

Announcements reflect the status of CycloGen AI programs at the time of publication. Forward-looking statements are subject to scientific, regulatory, and business uncertainties.

November 5, 2026

CycloGen AI Initiates Two Proprietary Oncology Discovery Programs

CycloGen AI has initiated two internal oncology discovery programs as part of its expanding AI-powered therapeutic discovery strategy.

The programs, designated CG-ONC-001 and CG-ONC-002, focus on early-stage small-molecule discovery and leverage CycloGen's integrated computational discovery platform.

The initiative represents an expansion of CycloGen's activities beyond enterprise discovery software into internally directed therapeutic research.

Both programs remain in early computational discovery, with future progression dependent on scientific evaluation and experimental validation.

View Therapeutic Pipeline →